|Traded as||Nasdaq Stockholm: ORX|
|Revenue||SEK 429.4 million (2013)|
|SEK 154.9 million (2013)|
Number of employees
|108 (2013) |
|Footnotes / references|
Employee and financial data as of 2014[update][needs update]
The company was founded in 1995 and their first product Diabact UBT, a breath test for diagnosing the causative agent of stomach ulcers (Helicobacter pylori), was introduced in 2000. In 2003, the company adopted the name Orexo and in 2005 the company was listed on the Stockholm Stock Exchange.
- Abstral, for the treatment of breakthrough cancer pain. It was approved in 2008 in Europe and for marketing in United States by the FDA in 2011.
- Edluar, for the treatment of short-term insomnia. FDA approved in 2009.
- Zubsolv a dissolvable tablet which combines the drugs buprenorphine and naloxone and treats opioid dependency and addiction. FDA approved in July 2013. Launched in the United States in September 2013 
- "2013 Annual Report". Orexo. 2014. Retrieved October 12, 2014.
- "History". Orexo. Retrieved July 5, 2013.
- Toni Clarke (July 4, 2013). "U.S. FDA approves Orexo drug to treat opioid addiction". Reuters. Retrieved July 5, 2013.
- Press releases - Orexo